NCT05059951Recruiting
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Source: ClinicalTrials.gov · Last updated 4 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15000 (estimated)
- First submitted
- 17 Sept 2021
- Start date
- 3 Oct 2021
- Primary completion date
- 15 Sept 2026
- Lead sponsor
- Hunan Province Tumor Hospital
- Diseases
- Lung cancer
- NCT number
- NCT05059951
What you commit to
- Study type: Observational
- Planned participants: 15000
- From 3 Oct 2021 to the primary completion date, 15 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients did not match for the Inclusion Criteria.
Who the study is looking for
- ≥18，Lung Cancer Confirmed by Histopathology
- Treated with Chemotherapy with or Without Checkpoint Inhibitors.
- ECOG 0 - 1.
- Predicted survival ≥ 12 weeks.
- Adequate bone marrow hematopoiesis and organ function
- Presence of measurable lesions according to RECIST 1.1.
- Subjects with stable brain metastases may be included in the study.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hunan Cancer Hospital Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.